Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Haemonetics Corporation stock | $70.98

Learn how to easily invest in Haemonetics Corporation stock.

Haemonetics Corporation is a medical instruments & supplies business based in the US. Haemonetics Corporation shares (HAE) are listed on the NYSE and all prices are listed in US Dollars. Haemonetics Corporation employs 2,708 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Haemonetics Corporation

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – HAE – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Haemonetics Corporation stock price (NYSE: HAE)

Use our graph to track the performance of HAE stocks over time.

Haemonetics Corporation shares at a glance

Information last updated 2021-10-17.
Latest market close$70.98
52-week range$49.26 - $142.11
50-day moving average $67.90
200-day moving average $67.38
Wall St. target price$79.25
PE ratio 55.7941
Dividend yield N/A (0%)
Earnings per share (TTM) $1.25

Buy Haemonetics Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Haemonetics Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Haemonetics Corporation price performance over time

Historical closes compared with the close of $70.98 from 2021-10-20

1 week (2021-10-14) 0.31%
1 month (2021-09-21) 0.75%
3 months (2021-07-21) 16.15%
6 months (2021-04-21) 2.00%
1 year (2020-10-21) -32.98%
2 years (2019-10-21) -44.22%
3 years (2018-10-19) 106.31
5 years (2016-10-21) 107.42%

Is Haemonetics Corporation under- or over-valued?

Valuing Haemonetics Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Haemonetics Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Haemonetics Corporation's P/E ratio

Haemonetics Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 56x. In other words, Haemonetics Corporation shares trade at around 56x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Haemonetics Corporation's PEG ratio

Haemonetics Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3382. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Haemonetics Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Haemonetics Corporation's EBITDA

Haemonetics Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $192.6 million.

The EBITDA is a measure of a Haemonetics Corporation's overall financial performance and is widely used to measure a its profitability.

Haemonetics Corporation financials

Revenue TTM $903.4 million
Operating margin TTM 11.64%
Gross profit TTM $428.5 million
Return on assets TTM 4.07%
Return on equity TTM 10.03%
Profit margin 7.14%
Book value $13.27
Market capitalisation $3.6 billion

TTM: trailing 12 months

Shorting Haemonetics Corporation shares

There are currently 2.0 million Haemonetics Corporation shares held short by investors – that's known as Haemonetics Corporation's "short interest". This figure is 0.4% down from 2.0 million last month.

There are a few different ways that this level of interest in shorting Haemonetics Corporation shares can be evaluated.

Haemonetics Corporation's "short interest ratio" (SIR)

Haemonetics Corporation's "short interest ratio" (SIR) is the quantity of Haemonetics Corporation shares currently shorted divided by the average quantity of Haemonetics Corporation shares traded daily (recently around 492099.51100245). Haemonetics Corporation's SIR currently stands at 4.09. In other words for every 100,000 Haemonetics Corporation shares traded daily on the market, roughly 4090 shares are currently held short.

However Haemonetics Corporation's short interest can also be evaluated against the total number of Haemonetics Corporation shares, or, against the total number of tradable Haemonetics Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Haemonetics Corporation's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Haemonetics Corporation shares in existence, roughly 40 shares are currently held short) or 0.0397% of the tradable shares (for every 100,000 tradable Haemonetics Corporation shares, roughly 40 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Haemonetics Corporation.

Find out more about how you can short Haemonetics Corporation stock.

Haemonetics Corporation share dividends

We're not expecting Haemonetics Corporation to pay a dividend over the next 12 months.

Have Haemonetics Corporation's shares ever split?

Haemonetics Corporation's shares were split on a 2:1 basis on 2 December 2012. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Haemonetics Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Haemonetics Corporation shares which in turn could have impacted Haemonetics Corporation's share price.

Haemonetics Corporation share price volatility

Over the last 12 months, Haemonetics Corporation's shares have ranged in value from as little as $49.26 up to $142.11. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Haemonetics Corporation's is 0.3074. This would suggest that Haemonetics Corporation's shares are less volatile than average (for this exchange).

Haemonetics Corporation overview

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, the company offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Frequently asked questions

What percentage of Haemonetics Corporation is owned by insiders or institutions?
Currently 0.636% of Haemonetics Corporation shares are held by insiders and 101.84% by institutions.
How many people work for Haemonetics Corporation?
Latest data suggests 2,708 work at Haemonetics Corporation.
When does the fiscal year end for Haemonetics Corporation?
Haemonetics Corporation's fiscal year ends in March.
Where is Haemonetics Corporation based?
Haemonetics Corporation's address is: 125 Summer Street, Boston, MA, United States, 02110
What is Haemonetics Corporation's ISIN number?
Haemonetics Corporation's international securities identification number is: US4050241003
What is Haemonetics Corporation's CUSIP number?
Haemonetics Corporation's Committee on Uniform Securities Identification Procedures number is: 405024100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site